Invictus RG Reduces Stake in Amedisys Inc (AMED)

Invictus RG trimmed its position in Amedisys Inc (NASDAQ:AMED) by 36.7% in the third quarter, Holdings Channel reports. The fund owned 2,302 shares of the health services provider’s stock after selling 1,332 shares during the quarter. Invictus RG’s holdings in Amedisys were worth $288,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new stake in Amedisys in the second quarter valued at $149,000. Moneta Group Investment Advisors LLC acquired a new stake in Amedisys in the second quarter valued at $181,000. Cubist Systematic Strategies LLC increased its holdings in Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after purchasing an additional 2,172 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in Amedisys in the third quarter valued at $203,000. Finally, Ibex Investors LLC acquired a new stake in Amedisys in the third quarter valued at $215,000. Institutional investors own 92.39% of the company’s stock.

Shares of Amedisys stock opened at $130.30 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a 1-year low of $49.80 and a 1-year high of $140.91. The stock has a market cap of $4.32 billion, a price-to-earnings ratio of 58.96, a price-to-earnings-growth ratio of 2.02 and a beta of 1.29.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.18. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The firm had revenue of $417.34 million during the quarter, compared to the consensus estimate of $411.05 million. During the same period last year, the business posted $0.56 EPS. The business’s revenue was up 11.7% compared to the same quarter last year. On average, sell-side analysts forecast that Amedisys Inc will post 3.58 earnings per share for the current year.

In other Amedisys news, insider David L. Kemmerly sold 6,500 shares of the stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $118.87, for a total transaction of $772,655.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christopher Gerard sold 7,892 shares of the stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $119.02, for a total value of $939,305.84. Following the sale, the chief operating officer now owns 29,429 shares of the company’s stock, valued at $3,502,639.58. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,486 shares of company stock valued at $4,449,649. Company insiders own 2.60% of the company’s stock.

A number of research firms recently weighed in on AMED. ValuEngine upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 28th. UBS Group began coverage on Amedisys in a report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price objective for the company. Bank of America set a $139.00 price objective on Amedisys and gave the company a “buy” rating in a report on Tuesday, September 18th. Cantor Fitzgerald began coverage on Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective for the company. Finally, Canaccord Genuity began coverage on Amedisys in a report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $107.08.

ILLEGAL ACTIVITY NOTICE: “Invictus RG Reduces Stake in Amedisys Inc (AMED)” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/12/08/invictus-rg-reduces-stake-in-amedisys-inc-amed.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Recommended Story: Benefits of owning preferred stock

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply